• Chairman Torsten Goesch, MD, PhD

    Partner, Rosetta Capital Limited, Dr. Torsten Goesch has been the director of Rosetta Capital, a secondary life science investor, since 2002, and is responsible for the management of several Rosetta Capital investments. As such, he has served on several biotech company boards, including those of Enobia Ltd, Forward Pharma SA and Cytochroma Ltd. Dr. Goesch is also the founder and former Managing Director of TRG Invest, a Munich-based consulting business serving companies in the life science sector. Additionally, Dr. Goesch served as the General Manager for the German Speaking Countries at Biogen from 1997-1999, and prior to that served as the Commercial Head of Merck KGaA’s worldwide generics drug business, Merck Generics. He practiced as a doctor of internal medicine at the University Hospital Hamburg-Eppendorf from 1988-1990, focusing on nephrology, immunology and oncology. Dr. Goesch has a Master of Management from Northwestern University’s J.L. Kellogg Graduate School of Management, as well as a M.D. and Ph.D. from Heinrich Heine University Düsseldorf

  • Viktor Drvota MD, Ph. D.

    CEO, Karolinska Development Viktor Drvota has over 13 years of Venture Capital experience with several investments, significant fundraisings, IPOs and exits. He was responsible for Life Science at SEB Venture Capital from 2002 to 2016. During his tenure at SEB VC, he also served as a board member in several biotech and medtech companies such as Arexis AB, SBL Vaccin AB, Nuevolution AS, Index Pharma AB, Scibase AB and Airsonett AB, among others. Before joining SEB, Dr Drvota worked as Senior Consultant and Associate Professor in Cardiology at Karolinska University Hospital, Stockholm. Dr. Drvota has experience from preclinical as well as clinical research in drug development and medical devices. Dr. Drvota has 29 published research articles.

  • Professor Gunvor Ekman-Ordeberg MD, PhD

    Since becoming a Specialist in Ob/Gyn in 1977 and earning her PhD 1982, Gunvor Ekman-Ordeberg has held leading positions at Karolinska Institutet, including Head of Obstetrics (1986-2000) and Professor of Obstetrics and Gynecology (2001-present). In 1986, Dr. Ekman-Ordeberg became the head of a research group with an international network and 25 PhDs from different countries. Dilafor originates from a clinical observation by Dr. Ekman-Ordeberg in the early 1980s which indicated that prophylactic LMWH was associated with an effective labor in term pregnant women. Dr. Ekman-Ordeberg and the research group have studied the delivery process in the clinic and by in human biopsies for more than 40 years. Findings from these experiments supported the clinical observations which formed the basis of the founding of Dilafor 2003 .

  • Fredrik Ahlström, Msc

    Investment Director, Praktikerinvest Fredrik Ahlström, Chief Executive Officer at Praktikertjänst AB:s Pensionsstiftelse and PraktikerInvest. Mr. Ahlstrom represents one of the major shareholders in Dilafor. Mr. Ahlström has a long financial background from the asset management industry with 25 years of experience, including as portfolio manager at Länsförsäkringar, Trygg Hansa, Gota Fonder and Chief Financial Officer at Praktikertjänst AB. He is currently chairman of Praktikertjänst Försäkringar AB, Praktikertjänst Fastigheter AB and Frenda AB. Mr. Ahlström holds a Msc in Econometric and Financial economics. He is also a CFA charter holder (Chartered Financial Analyst).

  • Marco Vecchia, Attorney-at-law

    Marco Vecchia is a lawyer and former General Counsel at Chiesi Farmaceutici for 37 years. He is a member of the Opocrin Board of Directors since 2008 and has extensive experience from business development and mergers acquisitions, IP and corporate governance.

  • Enrica Bovina, Industrial Pharmacist

    From 1996 to 2009, Mrs. Bovina held various positions in different pharmaceutical companies: 1996-1998 researcher at Glaxo Smith Kline; 1998-2002 Quality Control Manager at Fatro S.p.A ; 2002-2009 Qualified Person then Country Quality Assurance & Regulatory Affair Director at Cis bio radiopharmaceuticals. From 2009 to 2016, she held the position of Qualified Person at Opocrin S.p.A, where she was directly involved in the tech transfer, regulatory and quality aspects related to modified low molecular weight heparins, including Tafoxiparin. Since 2017 she holds the position of R&D Director at Opocrin, where she leads all the projects related to modified Heparins, LMW heparins, heparinoids and other biological and non biological Complex Drugs in the Company pipeline.

  • Johan Rasin, LL.M

    Johan Rasin has a Master of Laws LL.M from Uppsala University (1980). Mr Rasin has worked as a Tax attorney for the last 40 years, 10 years at Riksskatteverket (the Swedish National Tax Agency) and 30 years at Price Waterhouse Coopers and Grant Thornton. Mr Rasin was one of the first Tax Partners at Grant Thornton. His focus has mainly been on corporate taxation of listed companies, including international tax issues. From 2010 untill 2015 he also held the position as Risk Manager where he led the development of risk assessment for the Grant Thornton tax department. Mr Rasin is one of the original founders of Dilafor AB.